18F-FDG versus 68Ga-FAPI-46 as PET tracer in ER-positive breast cancer - a pilot study

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508066-15-00

Enrollment

Registered

2024-07-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hormone-positive breast cancer

Brief summary

To investigate the number of lesions detected on 18F-FDG PET but not on 68Ga-FAPI-46 PET and the number of lesions detected on 68Ga-FAPI-46 PET but not on 18F-FDG PET.

Detailed description

To investigate the number of lesions detected on 68Ga-FAPI-46 PET/CT but not on 68Ga-FAPI-46 PET/MRI and vice versa.

Interventions

DRUG68Ga-FAPI-46

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To investigate the number of lesions detected on 18F-FDG PET but not on 68Ga-FAPI-46 PET and the number of lesions detected on 68Ga-FAPI-46 PET but not on 18F-FDG PET.	—

Secondary

Measure	Time frame
To investigate the number of lesions detected on 68Ga-FAPI-46 PET/CT but not on 68Ga-FAPI-46 PET/MRI and vice versa.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026